Argenx rises on ‘strategically smart’ Unnatural Products acquisition
ARGX•Argenx shares rose 4% after the Belgian pharmaceutical company said it would acquire Unnatural Products in a deal valued at up to $1.15 billion (€1.03 billion). The acquisition is expected to close by the end of 2026.
1. Deal details
Argenx said it is acquiring US company Unnatural Products, adding a peptide discovery engine to broaden its immunology capabilities. The deal is expected to close by the end of 2026 and is valued at up to $1.15 billion (€1.03 billion).
2. Analyst views
KBC Securities called the acquisition validation of the potential of Argenx’s oral FcRn candidate, with further details expected in 2027, and kept its buy rating. It said the transaction will not affect Argenx’s 2026 expense guidance of around $4 billion. Van Lanschot Kempen called the deal “strategically smart,” citing recent clinical success of oral peptides and their potential to increasingly compete with injectables.
